Skip to main content
Clinical Trials/RPCEC00000284
RPCEC00000284
Recruiting
未知

Evaluation of the behavior of platelets count, EGF serum concentrations and the levels of lymphocytes subpopulations expression associated with the patient's immune status as possible biomarkers of effectiveness of CIMAvax-EGF vaccine.

Center of Molecular Immunology (CIM)0 sitesAugust 3, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
Advanced non small cell lung cancer
Sponsor
Center of Molecular Immunology (CIM)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 3, 2018
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Center of Molecular Immunology (CIM)

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients of any sex and age similar or more than 18 years.
  • 2\. Patients that complete the diagnostic criteria.
  • 3\. Patients included in another clinical trial in which the therapeutic vaccine CIMAvax\-EGF® is administered, or that they don't receive products in investigation and be managed follow up the Cuban Guide of treatment of patient with lung cancer 2016 version.
  • 4\. Patient that have signed the informed consent for the investigation.
  • 5\. Patient with performan status (ECOG) state from 0 at 3

Exclusion Criteria

  • 1\. Patient in fertile age that are not using an appropriate (intra\-uterine devices, hormonal contraceptives, barrier methods or bond of trumpets) method of contraception. For the males (vasectomy, use of preservatives) while the treatment lasts
  • 2\. Pregnant, lactating or puerperal patients.

Outcomes

Primary Outcomes

Not specified

Similar Trials